LACK OF DIVERSITY IN GUT MICROBIOME MAY INCREASE THE RISK OF HEART FAILURE
Compounds produced in our guts after eating dairy, eggs and red meat can also raise the risk
The gut microbiome is a delicately balanced community of trillions of bacteria, viruses, fungi and protozoa that live in the gastrointestinal tract and outnumber all the other cells in the body put together. The microbiome is known to have a major influence on our metabolism, weight, immune system and mood.
Now, a review of seven years of research carried out at Georgetown University School of Nursing & Health has found that having less biodiversity in our guts is linked to a greater risk of death due to heart disease.
The study also found that the presence of trimethylamine-N-oxide (TMAO), a compound produced by gut microbiota when we eat full-fat dairy products, egg yolks and red meat, can increase the risk.
To make the finding, the team reviewed more than 500 genetic and pharmacological studies published between 2014 and 2021 that associated the microbiome with heart failure, then whittled them down to the 30 that were most relevant, before analysing the combined findings.
“To diagnose and manage heart failure we rely on certain findings and test results, but we do not know how poor heart function influences the activities of the gut, including the absorption of food and medications,” said co-author Prof Kelley Anderson.
“There is now an appreciation of a back-and-forth relationship between the heart and elements in the gut, as clearly the heart and vascular system do not work in isolation – the health of one system can directly influence the other, but clear connections are still being worked out scientifically.”
According to the British Heart Foundation, heart and circulatory diseases are currently responsible for one-quarter of all deaths in the UK – that’s 160,000 deaths every year.
The researchers now plan to carry out a follow-up study to further investigate the connection between the gut microbiome and cardiovascular disease in contemporary patients.
“We are currently developing a forward-looking study to evaluate the microbiome in patients with heart failure. We are particularly interested in the symptomatic experience of patients with end-stage heart failure, as well as disease-related weight loss and wasting during this stage of cardiovascular disease,” said Anderson.